Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.57 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201942 | 1.00 | PARP1 (0.57) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL31589814 | 0.84 | CYSLTR1 (0.53) | KMT2ANPC1RAB9A | |
| SCHEMBL7949450 | 0.84 | CYSLTR1 (0.53) | KMT2ANPC1RAB9A | |
| SCHEMBL202108 | 0.83 | PARP1 (0.51) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL202107 | 0.83 | PARP1 (0.51) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL2562475 | 0.83 | PARP1 (0.57) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL203644 | 0.81 | PARP1 (0.56) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL1387269 | 0.81 | NPC1 (0.59) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL1387268 | 0.81 | NPC1 (0.59) | PARP1TNKSPARP15PARP14PARP10 | |
| SCHEMBL9636143 | 0.81 | PARP10 (0.61) | PARP1PARP15PARP14PARP10PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | PARP1 1024/4885TNKS 3159/4885PARP15 3929/4885 |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PARP1 1034/4885TNKS 4063/4885PARP15 4164/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | PARP1 1040/4885TNKS 2834/4885PARP15 4000/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PARP1 1034/4885TNKS 4063/4885PARP15 4164/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PARP1 1034/4885TNKS 4063/4885PARP15 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.